Pharsight Corp

Pharsight — Investor Presentation (February 2006)

31 slides from Pharsight's investor presentation, Feb 2, 2006

  1. Slide 1: Pharsight Corporation Investor Presentation February 2006

    Slide 1: Pharsight Corporation Investor Presentation February 2006

    Pharsight Corporation Investor Presentation February 2006 Shawn O’Connor President & CEO Exhibit 99.1 Confidential © Pharsight Corporation

  2. Slide 2: Executive Team

    Slide 2: Executive Team

    Executive Team Shawn O’Connor President & Chief Executive Officer QRS, Diasonics Ultrasound, Peat Marwick TBH Chief Financial Officer James Hayden SVP Global Sales Accelrys, Bio-Rad Laboratories, Raytheon Mark Hovde SVP Marketing Hovde Associates, Fast Track Systems, DataEdge Mona Sowiski SVP Drug D

  3. Slide 3: Pharsight

    Slide 3: Pharsight

    Pharsight

  4. Slide 4: Our Market Opportunity: Development Expenditure Estimates

    Slide 4: Our Market Opportunity: Development Expenditure Estimates

    Our Market Opportunity: Development Expenditure Estimates $0 $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000 $80,000 Branded Pharma Generics Biotech 2003 – 2008 CAGR Branded Pharma 8.6% Generics 22.6% Biotech 2.7% Total Pharma 11.0% Development Expenditure by Segment & Product Development Ph

  5. Slide 5: Return on Investment Example

    Slide 5: Return on Investment Example

    Return on Investment Example Aventis turned to a computer model from … Pharsight. Using its own animal and human test data, Aventis was able to simulate later-stage clinical trials. Based on that simulation, “we stopped funding development of the compound. The ratio between the therapeutic benefit a

  6. Slide 6: Return on Investment Example

    Slide 6: Return on Investment Example

    Return on Investment Example “Within 2 years of (implementing Pharsight’s WinNonlin automation and other measures) the two people conducting the routine pharmacokinetic studies had completed 45 studies in 1 year.” (previous staff of 19 for the same work) “The cycle time to issue final reports decrea

  7. Slide 7: Software Products

    Slide 7: Software Products

    Software Products Confidential © Pharsight, Inc.

  8. Slide 8: Overview of Key Software Offerings

    Slide 8: Overview of Key Software Offerings

    Overview of Key Software Offerings • Desktop Software Products – WinNonlin ® (“WNL™”) • Industry Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD” ) Modeling and Non Compartmental Analysis – Trial Simulator™ (“TS2™”) • Computer Assisted Clinical Trial Design & Simulation – WinNonMix ® (“WNM

  9. Slide 9: Key Software Offerings: WinNonlin

    Slide 9: Key Software Offerings: WinNonlin

    Key Software Offerings WinNonlin ® (“WNL™”) Industry Standard for Pharmacokinetic (“PK”), Pharmacodynamic (“PD ”) Modeling and Non Compartmental Analysis • Key Benefits – Used to simulate effects of different dosing regimens and changes in pharmacokinetic parameters required in regulatory submission

  10. Slide 10: Key Software Offerings: Trial Simulator

    Slide 10: Key Software Offerings: Trial Simulator

    Key Software Offerings State-of-the-Art Clinical Trial Design & Simulation Software • Market Opportunity – Total opportunity estimated by Pharsight at approx $29 million 25% market share = $7 million 50% market share = $15 million 75% market share = $22 million • Key Benefits – Minimize risk of tria

  11. Slide 11: Key Software Offerings: WinNonMix

    Slide 11: Key Software Offerings: WinNonMix

    Key Software Offerings WinNonMix ® (“WNM™”) Nonlinear Mixed Effects (Population) Analysis Software Application • Key Benefits – Extensive built-in library of PK, PD and PK-PD models – NONMEM data import wizard – Built-in report-ready graphics capability – Estimation algorithms for sparse and for ric

  12. Slide 12: Key Software Offerings: Pharsight Knowledgebase Server

    Slide 12: Key Software Offerings: Pharsight Knowledgebase Server

    Key Software Offerings Pharsight ® Knowledgebase Server™ (“PKS™”) Enterprise Data Management Systems for Secure Storage and Management of PK/PD Data • Market Opportunity – Total opportunity estimated by Pharsight at approx $187 million 25% market share = $47 million 50% market share = $94 million 75

  13. Slide 13: Key Software Offerings: Drug Model Explorer

    Slide 13: Key Software Offerings: Drug Model Explorer

    Key Software Offerings Drug Model Explorer™ (“DMX™”) Software-Based Communication Technology, Designed to Facilitate Quantitative Decision-Making in Drug Development • Market Opportunity – Total opportunity estimated by Pharsight at approx $33 million 25% market share = $8 million 50% market share =

  14. Slide 14: Strategic Consulting Services

    Slide 14: Strategic Consulting Services

    Strategic Consulting Services Confidential © Pharsight, Corporation

  15. Slide 15: Strategic Consulting Services

    Slide 15: Strategic Consulting Services

    Strategic Consulting Services Formal, quantitative, model-based decision-making method Increases drug development productivity Decreases late stage attrition Decreases time-to-market Reduces financial investment Improves clinical quality and commercial performance of final product

  16. Slide 16: Quantitative Modeling Supports Both Trial- and Program-Level Decisions

    Slide 16: Quantitative Modeling Supports Both Trial- and Program-Level Decisions

    Quantitative Modeling Supports Both Trial- and Program-Level Decisions Animal PK Data Human PK Data Treatment, Exposure Patient Endpoints Trial Outcomes Market Acceptance Drug and Patient Models Trial Models Market Models • Optimize treatment regimens and patient populations for the market and for a

  17. Slide 17: Strategic Consulting Services: Market Penetration – Current Clients

    Slide 17: Strategic Consulting Services: Market Penetration – Current Clients

    Strategic Consulting Services Market Penetration – Current Clients Current Clients Market Opportunity Current Clients Market Opportunity Top 10 Pharma ² 60% Market Penetration Top 50 Pharma ² 34% Market Penetration December 31, 2005 Pharma Exec 50: Pharmaceutical Executive, May 2004

  18. Slide 18: Financial Overview

    Slide 18: Financial Overview

    Financial Overview Confidential © Pharsight, Inc.

  19. Slide 19: FY05 Accomplishments and FY06 Objectives

    Slide 19: FY05 Accomplishments and FY06 Objectives

    FY05 Accomplishments FY06 Objectives Fiscal Year 2005 Results • Continued revenue growth • Y-Y revenue growth of 27% • 2 nd consecutive year of 25%+ growth • Profitability • Net income of $2.7 million, or 12% of revenues • Profitability in both business units • Achieved positive annual net cash flow

  20. Slide 20: Summary Statement of Operations - Y/Y

    Slide 20: Summary Statement of Operations - Y/Y

    Summary Statement of Operations - Y/Y Q3 FY06 and YTD FY06 ('000s except per share data) Q3 Q3 YTD YTD FY06 FY05 FY06 FY05 Revenues 5,757 $ 6,462 $ 17,371 $ 16,568 $ Cost of revenues 1,829 1,948 5,770 5,606 Gross profit 3,928 4,514 11,601 10,962 Operating expenses 3,636 3,024 10,741 8,851 Income fro

  21. Slide 21: Summary Operating Results – Software Products

    Slide 21: Summary Operating Results – Software Products

    Summary Operating Results – Software Products Q3 FY06 and YTD FY 06 ('000s) OPERATING RESULTS $ % $ % $ % $ % Revenues Initial license 1,672 $ 41% 2,391 $ 58% 3,793 $ 35% 4,425 $ 48% Renewal license 1,258 31% 1,127 27% 3,639 34% 3,387 44% Maintenance 7% 1% 7% 1% Services 21% 14% 2,365 22% 1,358 15%

  22. Slide 22: Summary Operating Results – Strategic Consulting

    Slide 22: Summary Operating Results – Strategic Consulting

    Summary Operating Results – Strategic Consulting Q3 FY06 and YTD FY 06 ('000s) OPERATING RESULTS Revenues 1,687 $ 100% 2,309 $ 100% 6,806 $ 100% 7,259 $ 100% Gross profit 20% 40% 2,572 38% 3,055 42% Income (loss) from operations (599) -36% 8% (755) -11% 4% FY06 FY05 Q3 Q3 YTD YTD FY06 FY05

  23. Slide 23: Quarterly Revenues

    Slide 23: Quarterly Revenues

    Quarterly Revenues (‘000s) $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05 Q1 FY06 Q2 FY06 Q3 FY06 Strategic Consulting Software Products

  24. Slide 24: Quarterly Gross Profit

    Slide 24: Quarterly Gross Profit

    Quarterly Gross Profit (Percentage of Segment Revenues) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05 Q1 FY06 Q2 FY06 Q3 FY06 Strategic Consulting Software Products

  25. Slide 25: Continued Profitability

    Slide 25: Continued Profitability

    Continued Profitability (‘000s) Q1 FY04 Q2 FY04 Q3 FY04 Q4 FY04 Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05 Q1 FY06 Q2 FY06 Q3 FY06 $3,500 $4,000 $4,500 $5,000 $5,500 $6,000 $6,500 Revenues Costs & Expenses Profitability achieved Q4 FY04

  26. Slide 26: Quarterly Operating Income

    Slide 26: Quarterly Operating Income

    Quarterly Operating Income (000s) $0 $500 $1,000 $1,500 Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05 Q1 FY06 Q2 FY06 Q3 FY06

  27. Slide 27: Quarterly Operating Cash Flow

    Slide 27: Quarterly Operating Cash Flow

    Quarterly Operating Cash Flow (‘000s) -$500 $0 $500 $1,000 $1,500 $2,000 $2,500 Q1 FY05 Q2 FY05 Q3 FY05 Q4 FY05 Q1 FY06 Q2 FY06 Q3 FY06

  28. Slide 28: Summary Balance Sheet

    Slide 28: Summary Balance Sheet

    Summary Balance Sheet December 31, 2005 ('000s) December 31, March 31, Cash & Cash Equivalents 9,974 $ 10,579 $ Accounts Receivable, Net 5,130 4,809 Total Current Assets 15,492 15,982 Total Assets 17,649 16,822 LIABILITIES & STOCKHOLDERS' DEFICIT A/P & Accrued Expenses 3,585 $ 3,497 $ Deferred Reven

  29. Slide 29: Pharsight

    Slide 29: Pharsight

    Pharsight

  30. Slide 30: Notices

    Slide 30: Notices

    Notices Proprietary Notice All contents Copyright ©2006 Pharsight Corporation. All rights reserved. The copyright for this document is owned by Pharsight Corporation. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopyi

  31. Slide 31

    Slide 31

Source: SEC EDGAR · 8-K filed Feb 2, 2006

More decks from Pharsight Corp